Biomarkers of cognitive decline in Parkinson's disease

Parkinsonism and Related Disorders

Volumn 21, Issue 5, 2015, Pages 431-443

  Lin, Chin Hsien ^a   Wu, Ruey Meei ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Biomarkers; Dementia; Genetic variants; Mild cognitive impairment; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; GLUCOSYLCERAMIDASE; IOMETOPANE I 123; METHYLPIPERIDIN 4 YL PROPIONATE C 11; N FLUOROPROPYL 2B CARBOMETHOXY 3B (4 IODOPHENYL)NORTROPANE I 123; RADIOPHARMACEUTICAL AGENT; TAU PROTEIN; UNCLASSIFIED DRUG;

BRAIN ATROPHY; BRAIN BLOOD FLOW; BRAIN METABOLISM; CEREBROSPINAL FLUID; CLINICAL FEATURE; COGNITIVE DEFECT; DEMENTIA; DIFFUSION TENSOR IMAGING; GENE MUTATION; GENETIC MARKER; HUMAN; LEWY BODY; MILD COGNITIVE IMPAIRMENT; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; COGNITION DISORDERS; HIPPOCAMPUS; METABOLISM; PATHOLOGY;

BIOMARKERS; COGNITION DISORDERS; HIPPOCAMPUS; HUMANS; PARKINSON DISEASE;

EID: 84928587880     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2015.02.010     Document Type: Review

References (180)

1. Chaudhuri K.R., Healy D.G., Schapira A.H. National Institute for Clinical Exellence. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006, 5:235-245.
2. Schrag A., Jahanshahi M., Quinn N. What contributes to quality of life in patients with Parkinson's disease?. JNeurol Neurosurg Psychiatry 2000, 69:308-312.
3. Aarsland D., Beyer M.K., Kurz M.W. Dementia in Parkinson's disease. Curr Opin Neurol 2008, 21:676-682.
4. Vossius C., Larsen J.P., Janvin C., Aarsland D. The economic impact of cognitive impairment in Parkinson's disease. Mov Disord 2011, 26:1541-1544.
5. Aarsland D., Andersen K., Larsen J.P., Lolk A., Nielsen H., Kragh-Sorensen P. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 2001, 56:730-736.
6. Litvan I., Goldman J.G., Troster A.I., Schmand B.A., Weintraub D., Petersen R.C., et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: movement Disorder Society Task Force guidelines. Mov Disord 2012, 27:349-356.
7. Aarsland D., Bronnick K., Larsen J.P., Tysnes O.B., Alves G. Norwegian ParkWest Study G. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 2009, 72:1121-1126.
8. Yu R.L., Wu R.M., Tai C.H., Lin C.H., Cheng T.W., Hua M.S. Neuropsychological profile in patients with early stage of Parkinson's disease in Taiwan. Parkinsonism Relat Disord 2012, 18:1067-1072.
9. Aarsland D., Andersen K., Larsen J.P., Perry R., Wentzel-Larsen T., Lolk A., et al. The rate of cognitive decline in Parkinson disease. Arch Neurol 2004, 61:1906-1911.
10. Stern Y., Marder K., Tang M.X., Mayeux R. Antecedent clinical features associated with dementia in Parkinson's disease. Neurology 1993, 43:1690-1692.
11. Williams-Gray C.H., Foltynie T., Brayne C.E., Robbins T.W., Barker R.A. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 2007, 130:1787-1798.
12. Kehagia A.A., Barker R.A., Robbins T.W. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol 2010, 9:1200-1213.
13. Aarsland D., Bronnick K., Williams-Gray C., Weintraub D., Marder K., Kulisevsky J., et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010 Sep 21, 75(12):1062-1069.
14. Foltynie T., Brayne C.E., Robbins T.W., Barker R.A. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain 2004, 127:550-560.
15. Williams-Gray C.H., Evans J.R., Goris A., Foltynie T., Ban M., Robbins T.W., et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009, 132:2958-2969.
16. Bohnen N.I., Kaufer D.I., Hendrickson R., Ivanco L.S., Lopresti B.J., Constantine G.M., et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. JNeurol 2006, 253:242-247.
17. Emre M., Aarsland D., Brown R., Burn D.J., Duyckaerts C., Mizuno Y., et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007, 22:1689-1707.
18. Gibb W.R., Lees A.J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. JNeurol Neurosurg Psychiatry 1988, 51:745-752.
19. Lippa C.F., Duda J.E., Grossman M., Hurtig H.I., Aarsland D., Boeve B.F., et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007, 68:812-819.
20. McKeith I.G., Dickson D.W., Lowe J., Emre M., O'Brien J.T., Feldman H., et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005, 65:1863-1872.
21. Salmon D.P., Galasko D., Hansen L.A., Masliah E., Butters N., Thal L.J., et al. Neuropsychological deficits associated with diffuse Lewy body disease. Brain Cogn 1996, 31:148-165.
22. Goldman J.G., Williams-Gray C., Barker R.A., Duda J.E., Galvin J.E. The spectrum of cognitive impairment in Lewy body diseases. Mov Disord 2014 Apr 15, 29(5):608-621.
23. Gomperts S.N., Rentz D.M., Moran E., Becker J.A., Locascio J.J., Klunk W.E., et al. Imaging amyloid deposition in Lewy body diseases. Neurology 2008, 71:903-910.
24. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. JPsychiatr Res 1975, 12:189-198.
25. Gill D.J., Freshman A., Blender J.A., Ravina B. The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson's disease. Mov Disord 2008, 23:1043-1046.
26. Reitan R.M., Wolfson D. The trail-making test 1993, Neuropsychology Press, Tucson, AZ. 2nd ed.
27. D.W Weschler adult intelligence scale-III 1991, the Psychological Corporation, New York.
28. Smith A. Symbol digits modality test 1973, Western Psychological Services, Los Angeles, CA.
29. Goodglass H., Kaplan E. Clock drawing test. Assessment of Aphasia and related disorders 1983, Lea and Febiger, Philadelphia, PA. 2nd ed.
30. D.W Weschler memory scale-III manual 1997, the Psychological Corporation, San Antonio, TX.
31. Benedict R.H.S.D., Groninger L., Dobraski M., Sphritz B. Revision of the brief visuospatial memory test: studies of normal performance, reliability, and validity. Psychol Assess 1996, 8:145-153.
32. Grober E., Buschke H., Crystal H., Bang S., Dresner R. Screening for dementia by memory testing. Neurology 1988, 38:900-903.
33. Morris J.C., Heyman A., Mohs R.C., Hughes J.P., van Belle G., Fillenbaum G., et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989, 39:1159-1165.
34. Aarsland D., Kvaloy J.T., Andersen K., Larsen J.P., Tang M.X., Lolk A., et al. The effect of age of onset of PD on risk of dementia. JNeurol 2007, 254:38-45.
35. Levy G., Tang M.X., Cote L.J., Louis E.D., Alfaro B., Mejia H., et al. Motor impairment in PD: relationship to incident dementia and age. Neurology 2000, 55:539-544.
36. Galvin J.E., Pollack J., Morris J.C. Clinical phenotype of Parkinson disease dementia. Neurology 2006, 67:1605-1611.
37. Aarsland D., Ballard C., Larsen J.P., McKeith I. Acomparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psychiatry 2001, 16:528-536.
38. Harding A.J., Broe G.A., Halliday G.M. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002, 125:391-403.
39. Boot B.P., Boeve B.F., Roberts R.O., Ferman T.J., Geda Y.E., Pankratz V.S., et al. Probable rapid eye movement sleep behavior disorder increases risk for mild cognitive impairment and Parkinson disease: a population-based study. Ann Neurol 2012, 71:49-56.
40. Baba T., Kikuchi A., Hirayama K., Nishio Y., Hosokai Y., Kanno S., et al. Severe olfactory dysfunction is a prodromal symptom of dementia associated with Parkinson's disease: a 3 year longitudinal study. Brain 2012, 135:161-169.
41. Anang J.B., Gagnon J.F., Bertrand J.A., Romenets S.R., Latreille V., Panisset M., et al. Predictors of dementia in Parkinson disease: a prospective cohort study. Neurology 2014 Sep 30, 83(14):1253-1260.
42. Kempster P.A., O'Sullivan S.S., Holton J.L., Revesz T., Lees A.J. Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. Brain 2010, 133:1755-1762.
43. Hurtig H.I., Trojanowski J.Q., Galvin J., Ewbank D., Schmidt M.L., Lee V.M., et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000, 54:1916-1921.
44. Irwin D.J., White M.T., Toledo J.B., Xie S.X., Robinson J.L., Van Deerlin V., et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 2012, 72:587-598.
45. Braak H., Rub U., Jansen Steur E.N., Del Tredici K., de Vos R.A. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 2005, 64:1404-1410.
46. Aarsland D., Andersen K., Larsen J.P., Lolk A., Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003, 60:387-392.
47. Mattila P.M., Rinne J.O., Helenius H., Dickson D.W., Roytta M. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol 2000, 100:285-290.
48. Aarsland D., Perry R., Brown A., Larsen J.P., Ballard C. Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol 2005, 58:773-776.
49. Mikolaenko I., Pletnikova O., Kawas C.H., O'Brien R., Resnick S.M., Crain B., et al. Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA). JNeuropathol Exp Neurol 2005, 64:156-162.
50. Compta Y., Parkkinen L., O'Sullivan S.S., Vandrovcova J., Holton J.L., Collins C., et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?. Brain 2011, 134:1493-1505.
51. Jellinger K.A., Attems J. Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol 2008, 115:427-436.
52. Jellinger K.A., Seppi K., Wenning G.K., Poewe W. Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. JNeural Transm 2002, 109:329-339.
53. Jellinger K.A. Morphological substrates of parkinsonism with and without dementia: a retrospective clinico-pathological study. JNeural Transm Suppl 2007, 91-104.
54. Kotzbauer P.T., Cairns N.J., Campbell M.C., Willis A.W., Racette B.A., Tabbal S.D., et al. Pathologic accumulation of alpha-synuclein and Abeta in Parkinson disease patients with dementia. Arch Neurol 2012, 69:1326-1331.
55. Hughes A.J., Daniel S.E., Blankson S., Lees A.J. Aclinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993, 50:140-148.
56. Sabbagh M.N., Adler C.H., Lahti T.J., Connor D.J., Vedders L., Peterson L.K., et al. Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord 2009, 23:295-297.
57. Pletnikova O., West N., Lee M.K., Rudow G.L., Skolasky R.L., Dawson T.M., et al. Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging 2005, 26:1183-1192.
58. Lashley T., Holton J.L., Gray E., Kirkham K., O'Sullivan S.S., Hilbig A., et al. Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson's disease patients. Acta Neuropathol 2008, 115:417-425.
59. Masliah E., Rockenstein E., Veinbergs I., Sagara Y., Mallory M., Hashimoto M., et al. beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A 2001, 98:12245-12250.
60. Clinton L.K., Blurton-Jones M., Myczek K., Trojanowski J.Q., LaFerla F.M. Synergistic interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. JNeurosci 2010, 30:7281-7289.
61. Lee V.M., Giasson B.I., Trojanowski J.Q. More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases. Trends Neurosci 2004, 27:129-134.
62. Giasson B.I., Forman M.S., Higuchi M., Golbe L.I., Graves C.L., Kotzbauer P.T., et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 2003, 300:636-640.
63. Hanganu A., Bedetti C., Degroot C., Mejia-Constain B., Lafontaine A.L., Soland V., et al. Mild cognitive impairment is linked with faster rate of cortical thinning in patients with Parkinson's disease longitudinally. Brain 2014 Apr, 137(Pt 4):1120-1129.
64. Ibarretxe-Bilbao N., Tolosa E., Junque C., Marti M.J. MRI and cognitive impairment in Parkinson's disease. Mov Disord 2009, 24:S748-S753.
65. Camicioli R., Moore M.M., Kinney A., Corbridge E., Glassberg K., Kaye J.A. Parkinson's disease is associated with hippocampal atrophy. Mov Disord 2003, 18:784-790.
66. Junque C., Ramirez-Ruiz B., Tolosa E., Summerfield C., Marti M.J., Pastor P., et al. Amygdalar and hippocampal MRI volumetric reductions in Parkinson's disease with dementia. Mov Disord 2005, 20:540-544.
67. Bouchard T.P., Malykhin N., Martin W.R., Hanstock C.C., Emery D.J., Fisher N.J., et al. Age and dementia-associated atrophy predominates in the hippocampal head and amygdala in Parkinson's disease. Neurobiol Aging 2008, 29:1027-1039.
68. Kenny E.R., Burton E.J., O'Brien J.T. Avolumetric magnetic resonance imaging study of entorhinal cortex volume in dementia with lewy bodies. A comparison with Alzheimer's disease and Parkinson's disease with and without dementia. Dement Geriatr Cogn Disord 2008, 26:218-225.
69. Ramirez-Ruiz B., Marti M.J., Tolosa E., Bartres-Faz D., Summerfield C., Salgado-Pineda P., et al. Longitudinal evaluation of cerebral morphological changes in Parkinson's disease with and without dementia. JNeurol 2005, 252:1345-1352.
70. Burton E.J., McKeith I.G., Burn D.J., O'Brien J.T. Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging. Mov Disord 2005, 20:1571-1576.
71. Beyer M.K., Janvin C.C., Larsen J.P., Aarsland D. Amagnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. JNeurol Neurosurg Psychiatry 2007, 78:254-259.
72. Song S.K., Lee J.E., Park H.J., Sohn Y.H., Lee J.D., Lee P.H. The pattern of cortical atrophy in patients with Parkinson's disease according to cognitive status. Mov Disord 2011, 26:289-296.
73. Weintraub D., Dietz N., Duda J.E., Wolk D.A., Doshi J., Xie S.X., et al. Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease. Brain 2012 Jan, 135(Pt 1):170-180.
74. Weintraub D., Doshi J., Koka D., Davatzikos C., Siderowf A.D., Duda J.E., et al. Neurodegeneration across stages of cognitive decline in Parkinson disease. Arch Neurol 2011 Dec, 68(12):1562-1568. 10.1001/archneurol.2011.725.
75. Segura B., Baggio H.C., Marti M.J., Valldeoriola F., Compta Y., Garcia-Diaz A.I., et al. Cortical thinning associated with mild cognitive impairment in Parkinson's disease. Mov Disord 2014 Oct, 29(12):1495-1503.
76. Beyer M.K., Aarsland D., Greve O.J., Larsen J.P. Visual rating of white matter hyperintensities in Parkinson's disease. Mov Disord 2006, 21:223-229.
77. Burton E.J., McKeith I.G., Burn D.J., Firbank M.J., O'Brien J.T. Progression of white matter hyperintensities in Alzheimer disease, dementia with lewy bodies, and Parkinson disease dementia: a comparison with normal aging. Am J Geriatr Psychiatry 2006, 14:842-849.
78. Marshall G.A., Shchelchkov E., Kaufer D.I., Ivanco L.S., Bohnen N.I. White matter hyperintensities and cortical acetylcholinesterase activity in parkinsonian dementia. Acta Neurol Scand 2006, 113:87-91.
79. Dalaker T.O., Larsen J.P., Dwyer M.G., Aarsland D., Beyer M.K., Alves G., et al. White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson's disease. NeuroImage 2009, 47:2083-2089.
80. Lee S.J., Kim J.S., Yoo J.Y., Song I.U., Kim B.S., Jung S.L., et al. Influence of white matter hyperintensities on the cognition of patients with Parkinson disease. Alzheimer Dis Assoc Disord 2010, 24:227-233.
81. Detre J.A., Leigh J.S., Williams D.S., Koretsky A.P. Perfusion imaging. Magn Reson Med 1992, 23(1):37-45.
82. Kamagata K., Motoi Y., Hori M., Suzuki M., Nakanishi A., Shimoji K., et al. Posterior hypoperfusion in Parkinson's disease with and without dementia measured with arterial spin labeling MRI. JMagn Reson Imaging 2011, 33:803-807.
83. Burton E.J., McKeith I.G., Burn D.J., Williams E.D., O'Brien J.T. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain 2004, 127:791-800.
84. Summerfield C., Junque C., Tolosa E., Salgado-Pineda P., Gomez-Anson B., Marti M.J., et al. Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study. Arch Neurol 2005, 62:281-285.
85. Beyer M.K., Aarsland D. Grey matter atrophy in early versus late dementia in Parkinson's disease. Parkinsonism Relat Disord 2008, 14:620-625.
86. Camicioli R., Gee M., Bouchard T.P., Fisher N.J., Hanstock C.C., Emery D.J., et al. Voxel-based morphometry reveals extra-nigral atrophy patterns associated with dopamine refractory cognitive and motor impairment in parkinsonism. Parkinsonism Relat Disord 2009, 15:187-195.
87. Sanchez-Castaneda C., Rene R., Ramirez-Ruiz B., Campdelacreu J., Gascon J., Falcon C., et al. Correlations between gray matter reductions and cognitive deficits in dementia with Lewy Bodies and Parkinson's disease with dementia. Mov Disord 2009, 24:1740-1746.
88. Lyoo C.H., Ryu Y.H., Lee M.S. Topographical distribution of cerebral cortical thinning in patients with mild Parkinson's disease without dementia. Mov Disord 2010, 25:496-499.
89. Camicioli R., Sabino J., Gee M., Bouchard T., Fisher N., Hanstock C., et al. Ventricular dilatation and brain atrophy in patients with Parkinson's disease with incipient dementia. Mov Disord 2011, 26:1443-1450.
90. Melzer T.R., Watts R., MacAskill M.R., Pitcher T.L., Livingston L., Keenan R.J., et al. Grey matter atrophy in cognitively impaired Parkinson's disease. JNeurol Neurosurg Psychiatry 2012, 83:188-194.
91. Compta Y., Ibarretxe-Bilbao N., Pereira J.B., Junque C., Bargallo N., Tolosa E., et al. Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia. Parkinsonism Relat Disord 2012, 18:941-947.
92. Bruck A., Kurki T., Kaasinen V., Vahlberg T., Rinne J.O. Hippocampal and prefrontal atrophy in patients with early non-demented Parkinson's disease is related to cognitive impairment. JNeurol Neurosurg Psychiatry 2004, 75(10):1467-1469.
93. Tam C.W., Burton E.J., McKeith I.G., Burn D.J., O'Brien J.T. Temporal lobe atrophy on MRI in Parkinson disease with dementia: a comparison with Alzheimer disease and dementia with Lewy bodies. Neurology 2005, 64:861-865.
94. Nagano-Saito A., Washimi Y., Arahata Y., Kachi T., Lerch J.P., Evans A.C., et al. Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology 2005, 64:224-229.
95. Jokinen P., Bruck A., Aalto S., Forsback S., Parkkola R., Rinne J.O. Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat Disord 2009, 15:88-93.
96. Dalaker T.O., Zivadinov R., Ramasamy D.P., Beyer M.K., Alves G., Bronnick K.S., et al. Ventricular enlargement and mild cognitive impairment in early Parkinson's disease. Mov Disord 2011, 26:297-301.
97. Lee J.E., Cho K.H., Song S.K., Kim H.J., Lee H.S., Sohn Y.H., et al. Exploratory analysis of neuropsychological and neuroanatomical correlates of progressive mild cognitive impairment in Parkinson's disease. JNeurol Neurosurg Psychiatry 2014, 85:7-16.
98. Hattori T., Orimo S., Aoki S., Ito K., Abe O., Amano A., et al. Cognitive status correlates with white matter alteration in Parkinson's disease. Hum Brain Mapp 2012, 33:727-739.
99. Zarei M., Ibarretxe-Bilbao N., Compta Y., Hough M., Junque C., Bargallo N., et al. Cortical thinning is associated with disease stages and dementia in Parkinson's disease. JNeurol Neurosurg Psychiatry 2013, 84:875-881.
100. Huang C., Mattis P., Perrine K., Brown N., Dhawan V., Eidelberg D. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 2008, 70:1470-1477.
101. Bohnen N.I., Koeppe R.A., Minoshima S., Giordani B., Albin R.L., Frey K.A., et al. Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. JNucl Med 2011, 52:848-855.
102. Bohnen N.I., Kaufer D.I., Ivanco L.S., Lopresti B., Koeppe R.A., Davis J.G., et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an invivo positron emission tomographic study. Arch Neurol 2003, 60:1745-1748.
103. Whitehouse P.J., Hedreen J.C., White C.L., Price D.L. Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol 1983, 13:243-248.
104. Gomperts S.N., Locascio J.J., Rentz D., Santarlasci A., Marquie M., Johnson K.A., et al. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology 2013, 80:85-91.
105. Petrou M., Bohnen N.I., Muller M.L., Koeppe R.A., Albin R.L., Frey K.A. Abeta-amyloid deposition in patients with Parkinson disease at risk for development of dementia. Neurology 2012, 79:1161-1167.
106. Edison P., Rowe C.C., Rinne J.O., Ng S., Ahmed I., Kemppainen N., et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. JNeurol Neurosurg Psychiatry 2008, 79:1331-1338.
107. Jokinen P., Scheinin N., Aalto S., Nagren K., Savisto N., Parkkola R., et al. [(11)C]PIB-, [(18)F]FDG-PET and MRI imaging in patients with Parkinson's disease with and without dementia. Parkinsonism Relat Disord 2010, 16:666-670.
108. Firbank M.J., Colloby S.J., Burn D.J., McKeith I.G., O'Brien J.T. Regional cerebral blood flow in Parkinson's disease with and without dementia. NeuroImage 2003, 20:1309-1319.
109. Muller U., Wachter T., Barthel H., Reuter M., von Cramon D.Y. Striatal [123I]beta-CIT SPECT and prefrontal cognitive functions in Parkinson's disease. JNeural Transm 2000, 107:303-319.
110. Colloby S.J., McParland S., O'Brien J.T., Attems J. Neuropathological correlates of dopaminergic imaging in Alzheimer's disease and Lewy body dementias. Brain 2012, 135:2798-2808.
111. Fodero-Tavoletti M.T., Mulligan R.S., Okamura N., Furumoto S., Rowe C.C., Kudo Y., et al. Invitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies. Eur J Pharmacol 2009, 617:54-58.
112. Nobili F., Abbruzzese G., Morbelli S., Marchese R., Girtler N., Dessi B., et al. Amnestic mild cognitive impairment in Parkinson's disease: a brain perfusion SPECT study. Mov Disord 2009, 24:414-421.
113. Mollenhauer B., Trenkwalder C., von Ahsen N., Bibl M., Steinacker P., Brechlin P., et al. Beta-amyloid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement Geriatr Cogn Disord 2006, 22:200-208.
114. Parnetti L., Tiraboschi P., Lanari A., Peducci M., Padiglioni C., D'Amore C., et al. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol Psychiatry 2008, 64:850-855.
115. Compta Y., Marti M.J., Ibarretxe-Bilbao N., Junque C., Valldeoriola F., Munoz E., et al. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov Disord 2009, 24:2203-2210.
116. Alves G., Bronnick K., Aarsland D., Blennow K., Zetterberg H., Ballard C., et al. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. JNeurol Neurosurg Psychiatry 2010, 81:1080-1086.
117. Montine T.J., Shi M., Quinn J.F., Peskind E.R., Craft S., Ginghina C., et al. CSF Abeta(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord 2010, 25:2682-2685.
118. Buongiorno M., Compta Y., Marti M.J. Amyloid-beta and tau biomarkers in Parkinson's disease-dementia. JNeurol Sci 2011, 310:25-30.
119. Siderowf A., Xie S.X., Hurtig H., Weintraub D., Duda J., Chen-Plotkin A., et al. CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology 2010, 75:1055-1061.
120. Compta Y., Pereira J.B., Ríos J., Ibarretxe-Bilbao N., Junqué C., Bargalló N., et al. Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study. Parkinsonism Relat Disord 2013, 19:717-724.
121. Alves G., Lange J., Blennow K., Zetterberg H., Andreasson U., Førland M.G., et al. CSF Aβ42 predicts early-onset dementia in Parkinson disease. Neurology 2014, 82:1784-1790.
122. Yarnall A.J., Breen D.P., Duncan G.W., Khoo T.K., Coleman S.Y., Firbank M.J., et al. Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology 2014, 82:308-316.
123. Lim X., Yeo J.M., Green A., Pal S. The diagnostic utility of cerebrospinal fluid alpha-synuclein analysis in dementia with Lewy bodies - a systematic review and meta-analysis. Parkinsonism Relat Disord 2013 Oct, 19(10):851-858.
124. Gao L., Tang H., Nie K., Wang L., Zhao J., Gan R., et al. Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis. Int J Neurosci 2014 Oct 2, [E-pub ahead of print].
125. Sako W., Murakami N., Izumi Y., Kaji R. Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis. Mov Disord 2014 Nov, 29(13):1599-1605.
126. Kang J.H., Irwin D.J., Chen-Plotkin A.S., Siderowf A., Caspell C., Coffey C.S., et al. Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 2013, 70:1277-1287.
127. Hall S., Ohrfelt A., Constantinescu R., Andreasson U., Surova Y., Bostrom F., et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012, 69:1445-1452.
128. Ballard C.G., Jones E.L. CSF alpha-synuclein as a diagnostic biomarker for Parkinson disease and related dementias. Neurology 2010, 75:1760-1761.
129. Stewart T., Liu C., Ginghina C., Cain K.C., Auinger P., Cholerton B., et al. Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. Am J Pathol 2014, 184:966-975. Parkinson Study Group DATATOP Investigators.
130. Hall S., Surova Y., Öhrfelt A., Zetterberg H., Lindqvist D., Hansson O. CSF biomarkers and clinical progression of Parkinson disease. Neurology 2015, 84:57-63.
131. Parnetti L., Farotti L., Eusebi P., Chiasserini D., De Carlo C., Giannandrea D., et al. Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease. Front Aging Neurosci 2014, 6:53.
132. Sharon R., Bar-Joseph I., Frosch M.P., Walsh D.M., Hamilton J.A., Selkoe D.J. The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 2003, 37:583-595.
133. Hansson O., Hall S., Öhrfelt A., Zetterberg H., Blennow K., Minthon L., et al. Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. Alzheimer's Res Ther 2014, 6:25.
134. Compta Y., Valente T., Saura J., Segura B., Iranzo A., Serradell M., et al. Correlates of cerebrospinal fluid levels of oligomeric- and total-asynuclein in premotor, motor and dementia stages of Parkinson's disease. JNeurol 2014, 10.1007/s00415-014-7560-z.
135. Lehnert S., Jesse S., Rist W., Steinacker P., Soininen H., Herukka S.K., et al. iTRAQ and multiple reaction monitoring as proteomic tools for biomarker search in cerebrospinal fluid of patients with Parkinson's disease dementia. Exp Neurol 2012, 234:499-505.
136. Leverenz J.B., Watson G.S., Shofer J., Zabetian C.P., Zhang J., Montine T.J. Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease. Parkinsonism Relat Disord 2011, 17:61-64.
137. Chen-Plotkin A.S., Hu W.T., Siderowf A., Weintraub D., Goldmann Gross R., Hurtig H.I., et al. Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol 2011, 69:655-663.
138. Menza M., Dobkin R.D., Marin H., Mark M.H., Gara M., Bienfait K., et al. The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson's disease. Psychosomatics 2010, 51:474-479.
139. Rocha N.P., Teixeira A.L., Scalzo P.L., Barbosa I.G., de Sousa M.S., Morato I.B., et al. Plasma levels of soluble tumor necrosis factor receptors are associated with cognitive performance in Parkinson's disease. Mov Disord 2014, 29:527-531.
140. Kurz M.W., Larsen J.P., Kvaloy J.T., Aarsland D. Associations between family history of Parkinson's disease and dementia and risk of dementia in Parkinson's disease: a community-based, longitudinal study. Move Disord 2006, 21:2170-2174.
141. Bonifati V. Genetics of Parkinson's disease-state of the art, 2013. Parkinsonism Relat Disord 2014, 20:S23-S28.
142. Shin C.W., Kim H.J., Park S.S., Kim S.Y., Kim J.Y., Jeon B.S. Two Parkinson's disease patients with alpha-synuclein gene duplication and rapid cognitive decline. Mov Disord 2010, 25:957-959.
143. Satake W., Nakabayashi Y., Mizuta I., Hirota Y., Ito C., Kubo M., et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 2009, 41:1303-1307.
144. Simon-Sanchez J., Schulte C., Bras J.M., Sharma M., Gibbs J.R., Berg D., et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009, 41:1308-1312.
145. Do C.B., Tung J.Y., Dorfman E., Kiefer A.K., Drabant E.M., Francke U., et al. Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease. PLoS Genet 2011, 7:e1002141.
146. De Marco E.V., Tarantino P., Rocca F.E., Provenzano G., Civitelli D., De Luca V., et al. Alpha-synuclein promoter haplotypes and dementia in Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet 2008, 147:403-407.
147. Goris A., Williams-Gray C.H., Clark G.R., Foltynie T., Lewis S.J., Brown J., et al. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol 2007, 62:145-153.
148. Mata I.F., Leverenz J.B., Weintraub D., Trojanowski J.Q., Hurtig H.I., Van Deerlin V.M., et al. APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. JAMA Neurol 2014 Sep 1, 10.1001/jamaneurol.2014.1455.
149. Sidransky E., Nalls M.A., Aasly J.O., Aharon-Peretz J., Annesi G., Barbosa E.R., et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. NEngl J Med 2009, 361:1651-1661.
150. Alcalay R.N., Caccappolo E., Mejia-Santana H., Tang M., Rosado L., Orbe Reilly M., et al. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology 2012, 78:1434-1440.
151. Neumann J., Bras J., Deas E., O'Sullivan S.S., Parkkinen L., Lachmann R.H., et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 2009, 132:1783-1794.
152. Seto-Salvia N., Pagonabarraga J., Houlden H., Pascual-Sedano B., Dols-Icardo O., Tucci A., et al. Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course. Mov Disord 2012, 27:393-399.
153. Harhangi B.S., de Rijk M.C., van Duijn C.M., Van Broeckhoven C., Hofman A., Breteler M.M. APOE and the risk of PD with or without dementia in a population-based study. Neurology 2000, 54:1272-1276.
154. Kurz M.W., Dekomien G., Nilsen O.B., Larsen J.P., Aarsland D., Alves G. APOE alleles in Parkinson disease and their relationship to cognitive decline: a population-based, longitudinal study. JGeriatr Psychiatry Neurol 2009, 22:166-170.
155. Lane R., He Y., Morris C., Leverenz J.B., Emre M., Ballard C. BuChE-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline. Mov Disord 2009, 24:392-400.
156. Pankratz N., Byder L., Halter C., Rudolph A., Shults C.W., Conneally P.M., et al. Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia. Mov Disord 2006, 21:45-49.
157. Camicioli R., Rajput A., Rajput M., Reece C., Payami H., Hao C., et al. Apolipoprotein E epsilon4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson's disease: relationship to dementia and hallucinations. Mov Disord 2005, 20:989-994.
158. Egensperger R., Bancher C., Kosel S., Jellinger K., Mehraein P., Graeber M.B. The apolipoprotein E epsilon 4 allele in Parkinson's disease with Alzheimer lesions. Biochem Biophys Res Commun 1996, 224:484-486.
159. Han S.H., Einstein G., Weisgraber K.H., Strittmatter W.J., Saunders A.M., Pericak-Vance M., et al. Apolipoprotein E is localized to the cytoplasm of human cortical neurons: a light and electron microscopic study. JNeuropathol Exp Neurol 1994, 53:535-544.
160. Helisalmi S., Linnaranta K., Lehtovirta M., Mannermaa A., Heinonen O., Ryynanen M., et al. Apolipoprotein E polymorphism in patients with different neurodegenerative disorders. Neurosci Lett 1996, 205:61-64.
161. Huang X., Chen P., Kaufer D.I., Troster A.I., Poole C. Apolipoprotein E and dementia in Parkinson disease: a meta-analysis. Arch Neurol 2006, 63:189-193.
162. Jasinska-Myga B., Opala G., Goetz C.G., Tustanowski J., Ochudlo S., Gorzkowska A., et al. Apolipoprotein E gene polymorphism, total plasma cholesterol level, and Parkinson disease dementia. Arch Neurol 2007, 64:261-265.
163. Koller W.C., Glatt S.L., Hubble J.P., Paolo A., Troster A.I., Handler M.S., et al. Apolipoprotein E genotypes in Parkinson's disease with and without dementia. Ann Neurol 1995, 37:242-245.
164. Kurz A., Egensperger R., Haupt M., Lautenschlager N., Romero B., Graeber M.B., et al. Apolipoprotein E epsilon 4 allele, cognitive decline, and deterioration of everyday performance in Alzheimer's disease. Neurology 1996, 47:440-443.
165. Marder K., Maestre G., Cote L., Mejia H., Alfaro B., Halim A., et al. The apolipoprotein epsilon 4 allele in Parkinson's disease with and without dementia. Neurology 1994, 44:1330-1331.
166. Martinoli M.G., Trojanowski J.Q., Schmidt M.L., Arnold S.E., Fujiwara T.M., Lee V.M., et al. Association of apolipoprotein epsilon 4 allele and neuropathologic findings in patients with dementia. Acta Neuropathol 1995, 90:239-243.
167. Parsian A., Racette B., Goldsmith L.J., Perlmutter J.S. Parkinson's disease and apolipoprotein E: possible association with dementia but not age at onset. Genomics 2002, 79:458-461.
168. Troster A.I., Fields J.A., Paolo A.M., Koller W.C. Absence of the apolipoprotein E epsilon4 allele is associated with working memory impairment in Parkinson's disease. JNeurol Sci 2006, 248:62-67.
169. Wakabayashi K., Kakita A., Hayashi S., Okuizumi K., Onodera O., Tanaka H., et al. Apolipoprotein E epsilon4 allele and progression of cortical Lewy body pathology in Parkinson's disease. Acta Neuropathol 1998, 95:450-454.
170. Williams-Gray C.H., Goris A., Saiki M., Foltynie T., Compston D.A., Sawcer S.J., et al. Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease. JNeurol 2009, 256:493-498.
171. Morley J.F., Xie S.X., Hurtig H.I., Stern M.B., Colcher A., Horn S., et al. Genetic influences on cognitive decline in Parkinson's disease. Mov Disord 2012, 27:512-518.
172. Guo J.L., Covell D.J., Daniels J.P., Iba M., Stieber A., Zhang B., et al. Distinct alpha-synuclein strains differentially promote tau inclusions in neurons. Cell 2013, 154:103-117.
173. Giasson B.I., Lee V.M., Trojanowski J.Q. Interactions of amyloidogenic proteins. Neuromol Med 2003, 4:49-58.
174. Kurz M.W., Schlitter A.M., Klenk Y., Mueller T., Larsen J.P., Aarsland D., et al. FMR1 alleles in Parkinson's disease: relation to cognitive decline and hallucinations, a longitudinal study. JGeriatr Psychiatry Neurol 2007, 20:89-92.
175. Guerreiro R., Wojtas A., Bras J., Carrasquillo M., Rogaeva E., Majounie E., et al. TREM2 variants in Alzheimer's disease. NEngl J Med 2013, 368:117-127.
176. Han S.H., Hulette C., Saunders A.M., Einstein G., Pericak-Vance M., Strittmatter W.J., et al. Apolipoprotein E is present in hippocampal neurons without neurofibrillary tangles in Alzheimer's disease and in age-matched controls. Exp Neurol 1994, 128:13-26.
177. Beyer M.K., Alves G., Hwang K.S., Babakchanian S., Bronnick K.S., Chou Y.Y., et al. Cerebrospinal fluid Aβ levels correlate with structural brain changes in Parkinson's disease. Mov Disord 2013, 28:302-310.
178. Maetzler W., Liepelt I., Reimold M., Reischl G., Solbach C., Becker C., et al. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 2009, 34:107-112.
179. Irwin D.J., Lee V.M., Trojanowski J.Q. Parkinson's disease dementia: convergence of alpha-synuclein, tau and amyloid-beta pathologies. Nat Rev Neurosci 2013, 14:626-636.
180. Morris C.M., Massey H.M., Benjamin R., Leake A., Broadbent C., Griffiths M., et al. Molecular biology of APO E alleles in Alzheimer's and non-Alzheimer's dementias. JNeural Transm Suppl 1996, 47:205-218.